Drug Trial Radar · NCT01929083
Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Last checked: Nov 19, 2026Latest source record: Oct 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Apr 2013
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association
- First posted
- Aug 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 21 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Female sex is an independent risk factor for the potentially fatal drug-induced arrhythmia (irregular heartbeat) known as torsades de pointes (TdP), which is associated with prolongation of the corrected QT (QTc) interval on the electrocardiogram (ECG). Mechanisms for this increased risk in women are not well-understood. QTc interval duration has been shown to fluctuate throughout the phases of the menstrual cycle. Evidence indicates that the QTc interval response to drugs that may cause TdP is greater during the menses and ovulation phases of the menstrual cycle, during which serum progesterone concentrations are lowest, and lesser during the luteal phase, during which serum progesterone concentrations are highest. Additional evidence from our laboratory suggests that progesterone may be protective against TdP. Specific Aim 1: Establish the influence of oral progesterone administration as a preventive method by which to diminish the degree of drug-induced QT interval prolongation in women. Working hypothesis: Oral progesterone administration effectively attenuates enhanced drug-induced QT interval response in women. To test this hypothesis, progesterone or placebo will be administered in a crossover fashion to women during the menses phase of the menstrual cycle. QTc interval response to low-dose ibutilide, a drug known to lengthen the QT interval, will be assessed. The primary endpoint will be individually-corrected QT interval (QTcI) response to ibutilide, in the presence and absence of progesterone, which will be assessed by: 1) Effect on maximum change in QTcI, and 2) Area under the QTcI interval-time curves (AUEC). At the conclusion of this study, we will have established that oral progesterone administration is a safe and effective method of attenuating drug-induced QT interval prolongation.
Conditions
- Prolonged QT Interval in EKG and Sudden Death
Interventions
ProgesteroneDrug
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
PlaceboDrug
Subjects will receive oral placebo two capsules once daily every evening for 7 days
IbutilideDrug
Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline (Pre-Ibutilide) QTcI IntervalsTime frame: After 7 days of progesterone or placebo, prior to receiving IV ibutilide
- Maximum Individual-corrected QT Interval (QTcI)Time frame: 0, 15 & 30 minutes, and 1, 2, 4, 6, 8, and 12 hours post-ibutilide administration
- Maximum % Change From Baseline in QTcI Intervals Following Ibutilide AdministrationTime frame: After 7 days of progesterone or placebo
- Area Under the QTcI - Time Curve (AUEC)Time frame: From beginning of 10-minute ibutilide infusion to 1 hour following ibutilide infusion
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Indiana Clinical Research Center
Indianapolis, Indiana
Purdue University
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.